

# **Exhibit 23**

2007 WL 1959225

Only the Westlaw citation is currently available.

NOT FOR PUBLICATION  
United States District Court,  
D. New Jersey.

In re HYPODERMIC PRODUCTS  
ANTITRUST LITIGATION  
This Document Relates To:

Jabo's Pharmacy, Inc.

v.

Becton Dickinson & Co., Civil  
Action No.: 05-CV-5892,  
and  
Drug Mart Tallman, Inc.

v.

Becton Dickinson & Co.,  
Civil Action No. 06-CV-0174.

MDL NO. 1730. | Master Docket No.  
05-CV-1602 (JLL/CCC). | June 29, 2007.

#### Attorneys and Law Firms

Gordon Ball, Ball & Scott, Knoxville, TN, James V. Bashian,  
Law Office of James V. Bashian, PC, Fairfield, NJ, Joel M.  
Silverstein, Stern & Kilcullen, Roseland, NJ, for Plaintiff.

R. Dale Grimes, Bass, Berry & Sims, PLC, Nashville, TN,  
Deborah A. Silodor, Gregory B. Reilly, Lowenstein Sandler,  
PC, Roseland, NJ, for Defendant.

#### Opinion

#### OPINION

LINARES, District Judge.

\*1 This matter comes before the Court on the motion of Defendant, Becton Dickinson & Company, to dismiss Plaintiffs' <sup>1</sup> Consolidated Class Action Complaint, <sup>2</sup> pursuant to Federal Rule of Civil Procedure 12(b)(6). For the reasons set forth in this Opinion, Defendant's motion is DENIED. <sup>3</sup>

#### BACKGROUND <sup>4</sup>

This matter arises from actions brought by healthcare providers and distributors in the pharmaceutical and medical device industry, against Defendant, a medical device manufacturer, which allegedly controls a dominant share of the relevant market for the hypodermic products at issue in this case. The Judicial Panel on Multidistrict Litigation has transferred several related actions to this Court for consolidated pretrial proceedings, pursuant to 28 U.S.C. § 1407. <sup>5</sup>

#### I. Historical Facts

Plaintiffs are pharmacies in Tennessee and New York which purchased various disposable hypodermic products manufactured by Becton through a distributor or wholesaler. (Compl., ¶¶ 1, 13-14). Becton, a New Jersey corporation founded in 1897, is a large healthcare product manufacturer, which has been the dominant manufacturer of syringes and other disposable hypodermic products in the United States for decades. (*Id.*, ¶¶ 3, 15, 46). "By the 1950s, Becton had become the leading U.S. hypodermic syringe manufacturer." (*Id.*, ¶ 46). The disposable hypodermic products at issue include relevant markets for: (1) disposable syringes and associated needles, (2) disposable blood collection tubes, (3) disposable blood collection tube holders, and (4) intravenous ("IV") catheter devices and their associated needles. (*Id.*, ¶ 2). Said products are referred to collectively in the Complaint as "Disposable Hypodermic Products." (*Id.*). Disposable Hypodermic Products come in safety and non-safety forms. (*Id.*, ¶ 48). The relevant geographic market for each of the Disposable Hypodermic Products is the entire United States. (*Id.*, ¶¶ 27, 34, 39, 44).

By way of background, the Complaint explains that, at all relevant times, Plaintiffs purchased Disposable Hypodermic Products from Becton through authorized distributors who do not set the prices for those products. (*Id.*, ¶ 49). In particular, the Complaint explains that a pharmacy negotiates a price for Disposable Hypodermic Products with Defendant, either directly or through a Group Purchasing Organization (hereinafter "GPO"). (*Id.*, ¶ 50). The authorized dealer then takes possession of Defendant's products and holds them in inventory until the pharmacy becomes in need of said products, at which time the authorized dealer delivers same. (*Id.*). The pharmacy then pays the authorized dealer the price it had negotiated with Becton, as well as a delivery or administrative fee. (*Id.*). The authorized dealer then pays Defendant the amount it collected from the pharmacy, which was "the amount already agreed to between Becton and the

[pharmacy] under applicable GPO agreements or otherwise directly with Becton.” (*Id.*).

\*2 The Complaint goes on to allege that “as a result of this purchasing process, there is effectively only one sale: the [pharmacy] purchases Becton Disposable Hypodermic Products at prices negotiated with Becton and then receives these Products from authorized distributors.” (*Id.*). Because authorized distributors have no control over the pricing of Becton’s products, they, therefore, act solely as a distribution agent, “temporarily holding inventory and then delivering the product purchased” by the pharmacy. (*Id.*, ¶ 51). Thus, the only price which the authorized distributors negotiate with Becton and/or the healthcare provider is the amount of the delivery and/or administrative fee associated with same. (*Id.*). “The fixed percentage the authorized distributor charges for distribution services is the same no matter the price the Class Member negotiates and then pays Becton, and the price a Class Member pays for Becton Disposable Hypodermic Products will be the same from all authorized distributors.” (*Id.*). The Complaint also explains that upon information and belief, Becton sells a portion of its Disposable Hypodermic Products to wholesalers, who then resell these products to indirect class members. (*Id.*, ¶ 55).

## II. Becton's Alleged Anti-Competitive Conduct

Beginning in the early 1980s, rival manufacturers began posing a threat to Becton’s dominance in the Disposable Hypodermic Products markets. (*Id.*, ¶ 47). As a result, Becton began engaging in certain anti-competitive and illegal practices, which served to foreclose competition in the relevant markets by suppressing competition from current competitors and/or product innovators, such as Terumo and Retractable (*Id.*, ¶ 6).

The specific anti-competitive practices set forth in the Complaint include: (1) Becton’s imposition of market share purchase requirements on persons purchasing Disposable Hypodermic Products, (2) Becton’s bundling of its goods for exclusionary and predatory purposes, (3) Becton’s exclusionary contracts with certain GPOs, and (4) Becton’s bundling of its goods with the goods of other manufacturers for exclusionary purposes. (*Id.*, ¶ 4). Such practices were specifically designed to “eliminate or lessen competition and unlawfully acquire and maintain monopoly and/or market power” in the four relevant markets mentioned above, namely: (1) disposable syringes and their associated needles, (2) disposable blood collection tubes, (3) disposable blood collection tube holders, and (4) IV catheters and their

associated needles. (*Id.*, ¶ 2). Erecting such artificial barriers in the form of anti-competitive conduct has “discouraged potential rivals from even attempting to invest the resources necessary to challenge Becton’s dominance in the markets for Disposable Hypodermic Products.” (*Id.*, ¶ 47). Moreover, the Complaint alleges that there are no pro-competitive efficiencies created through such predatory and exclusionary conduct. (*Id.*, ¶ 70).

### A. Market Share Purchase Requirements and Bundling

\*3 The Complaint also alleges that Becton uses exclusionary contracts in order to “bundle together for sale different types of products to protect and exploit its market power.” (*Id.*, ¶ 64). For example, Becton responded to bid requests from GPOs, by offering proposals to sell its Disposable Hypodermic Products along with unrelated products, thereby providing substantial financial incentives to customers which agreed to purchase all of the products included in the bundle. (*Id.*).

Pursuant to one such purchasing program, in order “to receive the purported benefit” of the bundle, “purchasers had to agree to fill at least 95% of their Disposable Hypodermic Product needs from Becton.” (*Id.*, ¶ 65). On the other hand, customers who purchased less than Becton’s suggested “compliance” levels of their Disposable Hypodermic Products needs from Becton were penalized by (1) having to pay higher prices for Disposable Hypodermic Products, (2) losing certain post-purchase rebates, and (3) having to re-pay past rebates received by Becton. (*Id.*).

Becton has also offered certain customers “conversion” bonuses and rebates, which served as an additional incentive to accept the bundle of Becton products. (*Id.*, ¶ 66). One such conversion program offered customers with one month’s worth of Disposable Hypodermic Products as an inducement to choose Becton as their “primary” Disposable Hypodermic Product supplier. (*Id.*). Under this program, customers became eligible for certain “premium” discounts on Becton products only if they agreed to use a “minimum of three of four Becton Dickinson safety product categories that include needles and syringes, IV catheters, surgical blades and blood collection.” (*Id.*). Because many of Becton’s competitors in the Disposable Hypodermic Product markets are smaller companies which sell much fewer products, “these competitors cannot profitably match Becton’s structured offers across product lines (because the combined discounts on all of the products in Becton’s bundle is in many cases greater than the entire price of a single product made

by another manufacturer).” (*Id.*, ¶ 67). As a result of such “deliberately designed” programs, a substantial portion of the Disposable Hypodermic Product markets has been foreclosed. (*Id.*, ¶ 68).

### **B. Exclusionary Contracts**

Finally, the Complaint alleges that anywhere between 68% to 98% of hospitals in this country currently belong to at least one GPO, which serves as a negotiating agent for healthcare providers. (*Id.*, ¶ 56). GPOs were originally designed as a way for hospitals to save money by pooling their purchasing power in order to negotiate lower prices for medical products and/or goods. (*Id.*, ¶ 57). Prior to 1986, any payments made by manufacturers to a GPO were considered an illegal “kickback,” which violated the Social Security Act’s “anti-kickback” provisions. (*Id.*). However, Congress amended the Social Security Act’s “anti-kickback” provisions in 1986 to create certain limited exceptions for amounts paid by vendors to a GPO. (*Id.*). Thus, according to the Complaint, in order to influence GPOs, such as Premier, Becton has rewarded them not only with substantial cash payments, but also with high administrative fees, and equity positions. (*Id.*, ¶ 58).

\*4 Becton also secured “commitment contracts” with certain GPOs—including Novation and Premier—which essentially required that they deal exclusively with Becton for all their Hypodermic Product needs. (*Id.*, ¶¶ 59-61). For example, in 1998, one such GPO, Premier, awarded Becton with a 7.5 year “sole-source” contract. (*Id.*, ¶ 59). Similarly, in 1999, Becton awarded another GPO, Novation, with a \$1 million payment-in addition to certain administrative fees—for a 4-year “sole-source” contract, whereby “Becton would be the only vendor approved by Novation to sell Disposable Hypodermic Products to Novation members.” (*Id.*). Such commitment or “sole-source” contracts were implemented to prevent healthcare providers from buying Disposable Hypodermic Products made by other manufacturers. (*Id.*, ¶ 60). In fact, “[i]f a Class member desired to purchase Disposable Hypodermic Products from a manufacturer that was not the chosen sole-source contractor for the GPO, the Class member risked losing numerous financial incentives.” (*Id.*).

Finally, Plaintiffs allege that Becton used exclusionary practices to unfairly and unlawfully limit competition from competing manufacturers of Disposable Hypodermic Products. (*Id.*, ¶ 71). For example, the Complaint alleges that in response to a growing threat to its monopoly power in the Disposable Hypodermic Product markets by

a Japanese corporation by the name of Terumo, Becton engaged in a program called “Block Terumo” in the late 1980s, “which entailed the use of an aggressive strategy that included the bundled pricing and contracting strategies described above and other similar exclusionary and predatory tactics.” (*Id.*, ¶ 72). Similar strategies were utilized by Becton to limit competition from another competitor—Retractable Technologies—in the late 1990s. (*Id.*, ¶¶ 73-74).

### **III. Market Effects of Becton's Alleged Anti-Competitive Conduct**

The Complaint alleges that the combined market effect of the foregoing anti-competitive actions have resulted in foreclosed competition and, thus, higher prices for all purchasers of Becton's Disposable Hypodermic Products. (*Id.*, ¶ 69). Thus, according to the Complaint, Becton's customers have paid more than they would have paid in the absence of such unlawful conduct, “contrary to Becton's representations that hospitals and other customers who purchased Becton's bundle would receive a financial benefit.” (*Id.*, ¶¶ 69, 77). Thus, not only were healthcare providers deprived of the opportunity to purchase competing Disposable Hypodermic Products, but they were also forced to pay Becton artificially inflated prices for same. (*Id.*, ¶ 77).

### **IV. The Consolidated Class Action Complaint**

In light of the foregoing, Plaintiffs brought this action, pursuant to Sections 4 and 16 of the Clayton Act, 15 U.S.C. §§ 15(a) and 26, to recover treble damages, equitable relief, and reasonable attorneys' fees for Defendant's alleged violation of Sections 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1-2, as well as Section 3 of the Clayton Act, 15 U.S.C. § 14. Plaintiffs filed the instant class action complaint on May 10, 2006, pursuant to Federal Rule of Civil Procedure 23(a), (b)(2) and (b)(3), on their behalf, and as representatives of the following class (hereinafter referred to as the “Class”):

\*5 All persons in the United States who purchased Disposable Hypodermic Products manufactured by Becton through Becton's authorized distributors, at any time during the period 1988 through the present (the “Class Period”). The Class excludes Becton, Becton's parents, subsidiaries and affiliates, as well as Becton's authorized distributors.

(Compl., ¶ 16). In the alternative, or in addition, Plaintiffs seek to bring this action on their own behalf and as representatives of the following class of persons and entities (hereinafter referred to as the “Indirect Class”):

All persons in Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin (the “Class Jurisdictions”), who purchased Disposable Hypodermic Products manufactured by Becton through a distributor or wholesaler at any time during the period 1988 through the present (the “Class Period”). The Class excludes Becton, Becton's parents, subsidiaries and affiliates, and all distributors or wholesalers.

(*Id.*, ¶ 17).

Count One of the Complaint alleges unreasonable restraint of trade, in violation of [Section 1](#) of the Sherman Act and Section 3 of the Clayton Act. Count Two of the Complaint alleges monopoly maintenance, in violation of [Section 2](#) of the Sherman Act, and Count Three alleges attempted monopolization also in violation of [Section 2](#) of the Sherman Act. Count Four alleges state antitrust law violations, brought only by the Indirect Class. Count Five alleges unjust enrichment, brought by the Indirect Class members in Arizona, District of Columbia, Florida, Hawaii, Iowa, Maine, Massachusetts, Montana, Nebraska, South Dakota, Tennessee, Utah, and Vermont. Count Six alleges also alleges unjust enrichment, brought by the Indirect Class members in Alabama, California, Michigan, Minnesota, Mississippi, Nevada, New Mexico, New York, North Carolina, North Dakota, West Virginia, and Wisconsin.

Defendant Becton now moves to dismiss the Complaint pursuant to [Federal Rule of Civil Procedure 12\(b\)\(6\)](#).

#### LEGAL STANDARD

The applicable inquiry under [Federal Rule of Civil Procedure 12\(b\)\(6\)](#) is well-settled. Courts must accept all well-pleaded allegations in the complaint as true and draw all reasonable inferences in favor of the non-moving party.<sup>6</sup> See *Scheuer v. Rhodes*, 416 U.S. 232, 236, 94 S.Ct. 1683, 40 L.Ed.2d 90 (1974), *abrogated on other grounds by Harlow v. Fitzgerald*, 457 U.S. 800, 102 S.Ct. 2727, 73 L.Ed.2d 396 (1982); *Allegheny Gen. Hosp. v. Philip Morris, Inc.*, 228 F.3d 429, 434-35 (3d Cir.2000). However, courts are not required to credit bald assertions or legal conclusions improperly alleged in the complaint. See *In re Burlington Coat Factory Sec. Litig.*, 114 F.3d 1410, 1429 (3d Cir.1997). Similarly, legal conclusions draped in the guise of factual allegations may not benefit from the presumption of truthfulness. See *In re Nice Sys., Ltd. Sec. Litig.*, 135 F.Supp.2d 551, 565 (D.N.J.2001).

\*6 “While a complaint attacked by a [Rule 12\(b\)\(6\)](#) motion to dismiss does not need detailed factual allegations, a plaintiff's obligation to provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and conclusions, and a formulaic recitation of a cause of action's elements will not do. Factual allegations must be enough to raise a right to relief above the speculative level on the assumption that all of the complaint's allegations are true.” *Bell Atl. Corp. v. Twombly*, --- U.S. ---, ---, 127 S.Ct. 1955, 1959, --- L.Ed.2d ---, --- (2007).<sup>7</sup> Ultimately, however, the question is not whether plaintiffs will prevail at trial, but whether they should be given an opportunity to offer evidence in support of their claims. *Scheuer*, 416 U.S. at 236.

Additionally, the Third Circuit has explained that antitrust complaints, in particular, should be liberally construed. *Commonwealth of Pa. ex rel. Zimmerman v. PepsiCo, Inc.*, 836 F.2d 173, 179 (3d Cir.1988). Although there is no heightened pleading standard in antitrust cases,<sup>8</sup> antitrust complaints are not exempt from the Federal Rules of Civil Procedure. See, e.g., *Zimmerman*, 836 F.2d at 179-80. In this vein, the Third Circuit has indicated that the pleading standard for “[Section 1](#) claims is the short and concise statement standard of Rule 8(a).”<sup>9</sup> *Lum v. Bank of Am.*, 361 F.3d 217, 228 (3d Cir.2004) (distinguishing the “short and concise statement” standard of Rule 8(a), generally applicable to antitrust claims, from the heightened “particularity” standard of Rule 9(b), applicable to antitrust claims sounding in fraud). In assessing the Rule 8(a) pleading standard in the context of antitrust cases, the United States Supreme Court has explained that “[w]hile a complaint attacked by a [Rule 12\(b\)\(6\)](#) motion to dismiss does not need detailed factual



allegations,” it must plead “enough facts to state a claim to relief that is plausible on its face.” *Bell Atl. Corp.*, 127 S.Ct. at 1964, 1974.<sup>10</sup> With this framework in mind, the Court turns now to the issues raised by Defendant in support of the instant motion.

## DISCUSSION

Becton argues that the Complaint should be dismissed for failure to state claims upon which relief can be granted based on the following: (1) Plaintiffs have not adequately alleged the essential elements or necessary facts of any of its federal antitrust claims, (2) Plaintiffs have not adequately alleged the essential elements of any state-law antitrust claims, (3) Plaintiffs lack standing to assert the Clayton Act claim, (4) Plaintiffs lack standing to assert certain state law claims, and (5) certain state claims fail as a matter of law.

### I. Federal Antitrust Claims

#### A. Elements of Claims

Defendant argues that Plaintiffs have failed to allege any of the required elements of an antitrust claim. (Def. Br. at 12). In particular, Defendant claims that the Complaint is deficient in alleging (1) a relevant market, (2) anti-competitive effects, (3) antitrust injury, (4) standing, and (5) unlawful “exclusive dealing” or “exclusionary conduct.” Because Defendant has presented the Court with such global pleading arguments, which allegedly relate to Counts One, Two and Three, it is not entirely clear to the Court which arguments relate to which claims, and therefore, the specific basis on which Defendant believes that Plaintiffs have failed to plead particular elements of any claim. As a result, the Court will begin its analysis by assessing, generally, whether the Complaint alleges the requisite elements of the federal antitrust claims,<sup>11</sup> and will then turn to Defendant’s broader pleading arguments, keeping in mind that antitrust complaints are liberally construed in this Circuit. See *PepsiCo, Inc.*, 836 F.2d at 179.

#### Count One

\*7 Count One of the Complaint alleges unreasonable restraint of trade, in violation of Section 1 of the Sherman Act and Section 3 of the Clayton Act. Section 1 of the Sherman Act provides that:

Every contract, combination in the form of trust or otherwise, or

conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding \$100,000,000 if a corporation, or, if any other person, \$1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

#### 15 U.S.C. § 1.

The Third Circuit has explained that there are four essential elements of a § 1 violation:

- (1) concerted action by the defendants;
- (2) that produced anti-competitive effects within the relevant product and geographic markets;
- (3) that the concerted action was illegal; and
- (4) that the plaintiff was injured as a proximate result of the concerted action.

*Queen City Pizza, Inc. v. Domino's Pizza, Inc.*, 124 F.3d 430, 442 (3d Cir.1997). Moreover, “[b]ecause § 1 of the Sherman Act ‘does not prohibit [all] unreasonable restraints of trade ... but only restraints effected by a contract, combination, or conspiracy,’ ‘[t]he crucial question’ is whether the challenged anticompetitive conduct ‘stem[s] from independent decision or from an agreement, tacit or express.’ “ *Bell Atl. Corp.*, 127 S.Ct. at 1964. As a result, “stating such a claim requires a complaint with enough factual matter (taken as true) to suggest that an agreement was made.” *Id.* at 1965.

Section 3 of the Clayton Act, in turn, provides that:

It shall be unlawful for any person engaged in commerce, in the course of such commerce, to lease or make a sale or contract for sale of goods ... or fix a price charged therefor, or discount from, or rebate upon, such price, on the condition, agreement, or understanding that the lessee or

purchaser thereof shall not use or deal in the goods ... of a competitor or competitors of the lessor or seller, where the effect of such lease, sale, or contract for sale or such condition, agreement, or understanding may be to substantially lessen competition or tend to create a monopoly in any line of commerce.

15 U.S.C. § 14. See *Town Sound and Custom Tops, Inc. v. Chrysler Motors Corp.*, 959 F.2d 468, 473 n. 2 (3d Cir.1992) (explaining that Section 3 of the Clayton Act was technically written to “cover exclusive dealing contracts (contracts requiring the purchaser not to deal in the goods of a competitor of the seller) but Congress also intended to cover tying arrangements.”).

Recovery under Section 3 of the Clayton Act generally requires: (1) an “exclusive dealing” arrangement, and (2) “the probable effect of the exclusion must be to substantially lessen competition in the market.” *Barr Labs., Inc. v. Abbott Labs.*, No. 87-4764, 1989 WL 60320, \*4 (D.N.J. June 1, 1989) (citing *Tampa Elec. Co. v. Nashville Coal Co.*, 365 U.S. 320, 327, 81 S.Ct. 623, 5 L.Ed.2d 580 (1961)).

\*8 Here, the Complaint alleges that Becton entered into anti-competitive arrangements with GPOs, such as Premier, whereby it would pay the GPOs “millions of dollars in cash payments,” as well as “equity positions,” with the expectation and/or understanding that said GPOs would then “favor Becton’s products, regardless of price, over those of Becton’s competitors.” (Compl., ¶ 58). The Complaint cites to an article from February 1997, which states that as a result of a recent deal between Becton and Premier, whereby Premier would “receive a portion of administrative fees in the form of warrants to buy Becton stock. If Becton Dickinson’s fortunes rise, buoyed in part by Premier purchases, so will the value of the stock held by Premier.” (*Id.*).

The Complaint also alleges that Becton entered into agreements with GPOs, certain hospitals and other customers which included “bundled financial incentives” and “exclusive dealing commitments.” (Compl., ¶ 81). For example, during 1999, it is alleged that Becton provided Novation, another GPO, with a \$1 million payment, on top of the 3% administrative fees, in exchange for a four-year “sole-source contract under which Becton would be the only vendor approved by Novation to sell Disposable Hypodermic Products to Novation members.” (*Id.*, ¶

59).<sup>12</sup> The Complaint further alleges that the object of such an arrangement was to prevent Class members from purchasing Disposable Hypodermic Products made by other manufacturers, because “[i]f a Class member desired to purchase Disposable Hypodermic Products from a manufacturer that was not the chosen sole-source contractor for the GPO, the Class member risked losing numerous financial incentives.” (*Id.*, ¶ 60). Accordingly, such arrangements served to significantly “impede and prevent competing Disposable Hypodermic Product manufacturers from selling significant (if any) Disposable Hypodermic Products to healthcare providers that used those GPOs.” (*Id.*, ¶ 61).

Moreover, a plaintiff must allege facts establishing an “antitrust injury.” See *Schuykill Energy Res., Inc. v. Pa. Power & Light*, 113 F.3d 405, 413, 417 (3d Cir.1997) (recognizing that the existence of antitrust injury is not typically resolved through motions to dismiss). In this regard, the Complaint alleges that Plaintiffs were injured by Becton’s exclusionary practices, including its “sole-source” arrangements with certain GPOs, to the extent that they were forced to pay higher prices for Disposable Hypodermic Products than they would have paid in the absence of such practices and/or arrangements. (Compl., ¶¶ 62, 84, 92, 98).

### Count Two

Count Two of the Complaint alleges monopoly maintenance in violation of Section 2 of the Sherman Act. Section 2 of the Sherman Act provides that:

Every person who shall monopolize, or attempt to monopolize, or combine or conspire with any other person or persons, to monopolize any part of the trade or commerce among the several States, or with foreign nations, shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding \$100,000,000 if a corporation, or, if any other person, \$1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

\*9 15 U.S.C. § 2.

The Third Circuit has indicated that a § 2 violation generally consists of two elements: “(1) possession of monopoly power [in the relevant product market] and (2) ‘... maintenance of that power as distinguished from growth or development as a consequence of a superior product, business acumen, or historic accident.’” *United States v. Dentsply Int’l*, 399 F.3d 181, 186 (3d Cir.2005) (citing *Eastman Kodak Co. v. Image Technical Servs., Inc.*, 504 U.S. 451, 480, 112 S.Ct. 2072, 119 L.Ed.2d 265 (1992)). The Complaint alleges that Becton possesses monopoly power in the Disposable Syringe and Blood Collection Tube and Blood Collection Tube Holder markets, in the United States. (Compl., ¶ 86). The Complaint also alleges that in order to maintain such monopoly power, “Becton has willfully and unlawfully used exclusionary and predatory conduct, including but not limited to, bundled pricing with the intent to foreclose competition, and exclusionary agreements.” (*Id.*, ¶ 88). The Complaint likewise alleges that Becton's monopoly power in the Disposable Syringe, Blood Collection Tube and Blood Collection Tube Holder markets is not the result of “superior product offerings, good faith business acumen, or historical accident.” (*Id.*, ¶¶ 90). Rather, it is the result of certain “deliberately designed” programs and/or arrangements with GPOs and healthcare providers, including but not limited to, commitment contracts, bundling contracts, and conversion bonuses. (*Id.*, ¶¶ 58, 59, 65-68).<sup>13</sup>

### Count Three

Count Three of the Complaint alleges attempted monopolization, in violation of Section 2 of the Sherman Act. “To state a claim for attempted monopolization, a plaintiff must allege ‘(1) that the defendant has engaged in predatory or anticompetitive conduct with (2) a specific intent to monopolize and (3) a dangerous probability of achieving monopoly power.’” *Schuylkill Energy Res., Inc. v. Pa. Power & Light Co.*, 113 F.3d 405, 413 (3d Cir.1997) (citation omitted). The Complaint alleges that, “to the extent that Becton does not possess monopoly power in the Disposable Syringe, Blood Collection Tube and/or Blood Collection Tube Holder markets in the United States, it has unlawfully attempted to monopolize the markets for Disposable Syringes, Blood Collection Tubes and/or Blood Collection Tubes.” (Compl., ¶ 94). In particular, the Complaint alleges that Becton engaged in exclusionary and predatory conduct, including bundled pricing and exclusionary agreements, with the “specific intent” of achieving its goal of obtaining a monopoly in the foregoing

markets. (*Id.*, ¶¶ 95, 96). For example, the Complaint explains that Becton engaged in a program called “Block Terumo,” as a result of “the growing threat” posed by the price reductions of a competitor, Terumo. (*Id.*, ¶ 72). The Complaint goes on to allege that, as a result of the implementation of the “exclusionary and predatory sales tactics” (i.e., the “Block Terumo” program) “Terumo's market share in the United States for the Disposable Hypodermic Products went from approximately 12% to approximately 1%.” (*Id.*). By 1992, “Terumo announced that it would no longer focus on selling hypodermic products to hospitals in the United States,” thus illustrating that “there is a dangerous probability that if left unchecked, Becton will achieve its goals of obtaining monopoly power in said markets. (*Id.*, ¶¶ 72, 97).<sup>14</sup>

### B. Generally

#### Relevant Market

\*10 Turning now to Defendant's arguments, Defendant claims that Plaintiffs have failed to set forth the requisite relevant market. (Def. Br. at 12). In particular, Defendant claims that (1) Plaintiffs improperly combine “safety and conventional products without any allegations of the reasonable interchangeability and cross-elasticity of demand,” and (2) Plaintiffs' definition of the “IV” catheter market,” which includes winged IV catheters does not allege whether these products “can be interchanged, used to perform the same clinical functions or substituted for each other in medical practice.” (*Id.* at 13).

The Third Circuit has explained that Plaintiffs have the burden of defining the relevant market, and that the “outer boundaries of a product market are determined by the reasonable interchangeability of use or the cross-elasticity of demand between the product itself and substitutes for it.” *Queen City Pizza, Inc. v. Domino's Pizza, Inc.*, 124 F.3d 430, 436 (3d Cir.1997) (internal citations omitted). In *Queen City Pizza*, the Court went on to explain that:

Where the plaintiff fails to define its proposed relevant market with reference to the rule of reasonable interchangeability and cross-elasticity of demand, or alleges a proposed relevant market that clearly does not encompass all interchangeable substitute products even when all factual inferences are granted in plaintiff's favor, the relevant market



is legally insufficient and a motion to dismiss may be granted.

### Anti-Competitive Effects

*Id.*

The Complaint alleges four relevant product markets: (1) disposable syringes and associated needles, (2) disposable blood collection tubes, (3) disposable blood collection tube holders, and (4) intravenous catheter devices and their associated needles. (Compl., ¶ 2). The Complaint likewise alleges that there is no product “that can reasonably be substituted for” any of the products comprising the relevant product markets. (*Id.*, ¶¶ 28, 33, 38, 43). Defendant is correct in noting that the Complaint alleges that each of the four products at issue come in safety and non-safety forms. (*Id.*, ¶¶ 26, 37, 48). To the extent that Defendant urges the Court to conclude, based on the foregoing allegations, (1) that the two versions of each product, therefore, comprise separate product markets, and (2) that “folding these two separate markets into one general market creates an implausible product market,”<sup>15</sup> the Court determines that any such determination would be improper at this juncture.<sup>16</sup> See, e.g., *Fineman v. Armstrong World Indus., Inc.*, 980 F.2d 171, 199 (3d Cir.1992) (“the determination of a relevant product market or submarket (“market”) is a highly factual one best allocated to the trier of fact.”); *Weiss v. York Hosp.*, 745 F.2d 786, 825 (3d Cir.1984) (“Market definition is a question of fact.”).

Defendant also makes the cursory argument that Plaintiffs’ definition of the “IV catheter market,” which includes winged IV catheters does not allege whether these products “can be interchanged, used to perform the same clinical functions or substituted for each other in medical practice,” without citing to the relevant portion of the Complaint which allegedly defines the “IV catheter market” as such. (Def. Br. at 13). Although the Complaint does allege that Becton manufactures IV Catheters “including Winged IV Catheters,” the Complaint does not expressly allege that the “Winged IV Catheters” necessarily fall within the relevant product market of “IV Catheters and their Associated Needles.” (Compl., ¶¶ 42, 43). Moreover, the Complaint *does* allege that “[a] relevant product market exists for the sale of IV Catheters and their associated needles and the market segments thereunder,” and that “no product ... can be substituted for IV Catheters and their associated needles to fill this medical need.” (*Id.*, ¶ 43) (emphasis added).

\*11 Defendant claims that the Complaint “contains no particularized allegations about competition in any specific market. Plaintiffs never once identify any specific product as the subject of an exclusive contract or a bundled discount. Nor do they ever allege that any specific contract or agreement impacted any specific product market or any specific competitor within that market.” (Def. Br. at 15). Additionally, Defendant argues that the Complaint “is silent about the competitive dynamics or prices in any specific product market. Nor does the ... Complaint allege what specific competitors (or would-be competitors) participated in, and were supposedly excluded from, which of the specific product markets.” (*Id.* at 16). However, Defendant cites to no legal authority indicating that such particularized allegations are a pleading requirement.<sup>17</sup> To the contrary, the Supreme Court has reiterated that “Federal Rule of Civil Procedure 8(a) (2) requires only ‘a short and plain statement of the claim showing that the pleader is entitled to relief,’ in order to ‘give the defendant fair notice of what the ... claim is and the grounds upon which it rests.’” *Bell Atlantic Corp.*, 127 S.Ct. at 1964 (quoting *Conley v. Gibson*, 355 U.S. 41, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957)).<sup>18</sup> The Court recognizes that the Third Circuit has applied a heightened pleading standard in antitrust cases sounding in fraud. See, e.g., *Lum*, 361 F.3d at 228 (distinguishing the “short and concise statement” standard of Rule 8(a), generally applicable to antitrust claims, from the heightened “particularity” standard of Rule 9(b), applicable to antitrust claims sounding in fraud). However, Defendant does not suggest that the antitrust claims alleged in the Complaint sound in fraud.<sup>19</sup> Therefore, the Court sees no reason why it should apply the more rigorous pleading standard contemplated by Defendant to the case at hand.<sup>20</sup>

In any event, the Complaint does provide examples of the types of exclusionary practices allegedly utilized by Becton, and the purported effects of same. For example, the Complaint alleges that from 1998 through 1999, Becton engaged in securing commitment or “sole-source” contracts with certain GPOs, including Premier and Novation, which required that they deal exclusively with Becton for any hypodermic product needs, in return for a substantial monetary payment. (*Id.*, ¶ 59). The Complaint also alleges that pursuant to Becton’s purchasing programs, unrelated products from different product lines were “bundled” together for sale to hospitals and other healthcare providers whereby

in order “to receive the purported benefit offered under the bundle, purchasers had to agree to fill at least 95% of their Disposable Hypodermic Product needs from Becton.” (*Id.*, ¶¶ 64, 65). As an additional incentive, Plaintiffs also allege that Becton offered “conversion” programs. The Complaint goes on to list two examples of such programs, one of which provided a particular Class member with the ability to purchase Becton products at a premium discount only if it agreed to utilize a “minimum of three of four Becton Dickinson safety product categories that include needles and syringes, IV catheters, surgical blades and blood collection.” (*Id.*, ¶ 66).

**\*12** In addressing the anti-competitive effects of such programs, the Complaint alleges the following:

Many of Becton's competitors in the Disposable Hypodermic Product markets are smaller, specialized companies that sell fewer products, and in some instances only a single product. As a result, these competitors cannot profitably match Becton's structured offers across product lines (because the combined discounts on all of the products in Becton's bundle is in many cases greater than the entire price of a single product made by another manufacturer). In certain cases, even if the competitor offered substantial discounts on Disposable Hypodermic Products (or indeed gave them away for free), it could not ‘replace’ all the discounts and rebates that the buyer would ‘lose’ as a penalty for rejecting Becton's bundle.

(*Id.*, ¶ 67). For instance, the Complaint alleges that beginning in the 1970s, one particular competitor, Terumo, “which manufactures certain disposable medical products, including disposable syringes and associated needles”—one of the relevant product markets at issue—began gaining approximately 12% of the United States market for various hypodermic products. (Compl., ¶ 71). However, by 1992—as a direct result of certain exclusionary initiatives undertaken by Becton—Terumo's market share dropped to approximately 1%, and it ultimately ceased focusing on selling any hypodermic products to hospitals in the United States. (*Id.*, ¶ 72). This, the Complaint alleges, demonstrates that Becton's actions effectively foreclosed competition in the relevant product

markets, forcing Plaintiffs to pay higher prices for Disposable Hypodermic Products than they would have paid in the absence of Becton's exclusionary practices. (*Id.*, ¶¶ 67, 68, 69).

The Court finds such allegations of anti-competitive conduct set forth in the Complaint to be in sharp contrast with the allegations found to be insufficient in *Bell Atl. Corp.*, 127 S.Ct. at 1962-63.<sup>21</sup> In particular, the complaint at issue in *Bell Atl. Corp.* sought to demonstrate anticompetitive agreements based on parallel conduct through *inference*. *Id.* at 1962. To the contrary, the instant Complaint sets forth allegations of specific anti-competitive agreements—between Becton and certain GPOs, and between Becton and certain manufacturers—which the Court deems as providing Defendant with adequate notice of the particular grounds upon which Plaintiffs' claims rest, particularly given the fact that Plaintiffs have not yet had the benefit of discovery.<sup>22</sup> See, e.g., *Hosp. Bldg. Co. v. Trs. of Rex Hosp.*, 425 U.S. 738, 746-747, 96 S.Ct. 1848, 48 L.Ed.2d 338 (1976) (explaining that “in antitrust cases, where ‘the proof is largely in the hands of the alleged conspirators,’ dismissals prior to giving the plaintiff ample opportunity for discovery should be granted very sparingly”) (quotation omitted).

### *Antitrust Injury*

Defendant argues that Plaintiffs cannot state a claim because the “vague” allegations of antitrust injury set forth in the Complaint lack the requisite specificity. (Def. Br. at 25-26). Defendant also argues that “[s]ince a plaintiff ordinarily must be a participant in the relevant market to suffer antitrust injury, MedStar cannot state a claim without alleging the specific market in which it buys or sells products.” (*Id.* at 26).

**\*13** In support of its argument that the allegations of antitrust injury contained in the Complaint are overly vague, Defendant presents the following hypothetical questions for the Court's consideration—“Plaintiffs claim that they ‘incurred overcharges’ for some unspecified products. What were those products? In what markets are plaintiffs consumers?” (Def. Br. at 16). Even assuming, *arguendo*, that the Complaint does not specifically answer those questions, once again, Defendant cites to no legal authority indicating that antitrust injury must be plead with such specificity,<sup>23</sup> or that the antitrust injury alleged by Plaintiffs is somehow implausible. The Complaint alleges that “[b]y unlawfully excluding and impairing competition [in the four relevant product markets], Becton's conduct has caused Plaintiffs and the other Class

members to pay more for Disposable Hypodermic Products than they otherwise would have paid absent Becton's illegal, exclusionary conduct.” (Compl., ¶ 62). Defendant has given the Court no specific basis on which to find such a pleading of antitrust injury to be insufficient.<sup>24</sup>

In the alternative, Defendant cites to *Schuykill Energy Res., Inc. v. Pa. Power & Light*, 113 F.3d 405, 415 (3d Cir.1997), for the proposition that “[a] plaintiff who is neither a competitor nor a consumer in the relevant market does not suffer antitrust injury.” (Def. Br. at 16). To the extent that Defendant moves to dismiss the Complaint on such a basis, any such request is denied. The United States Supreme Court has recognized that an antitrust injury can be suffered by a plaintiff, even if the plaintiff “was not a competitor of the conspirators, [where] the injury she suffered was inextricably intertwined with the injury the conspirators sought to inflict on psychologists and the psychotherapy market.” *Blue Shield of Va. v. McCready*, 457 U.S. 465, 484, 102 S.Ct. 2540, 73 L.Ed.2d 149 (1982)). There, the Court went on to explain that “[i]n light of the conspiracy here alleged we think that McCready's injury ‘flows from that which makes defendants' acts unlawful’ within the meaning of *Brunswick*, and falls squarely within the area of congressional concern.” *Id.*

The Third Circuit has likewise found that a terminal operator plaintiff lacked standing to assert antitrust injury in the soda ash market-in which it was neither a consumer nor a competitor-because the plaintiff had “made no showing of a connection between the alleged international soda ash conspiracy and the level of competition within the terminalling market.” *Int'l Raw Materials, Ltd.*, 978 F.2d at 1327-29. There, the Court explained “[b]ecause IRM is neither a competitor nor a consumer in the relevant market, it must allege a significant causal connection between the alleged soda ash conspiracy and the alleged anticompetitive effects in the terminalling market such that the harm to the terminalling market can be said to be ‘inextricably intertwined’ with the alleged soda ash cartel.” *Id.* at 1327 (quoting *McCready*, 457 U.S. at 484). See also *Gulfstream III Assocs., Inc. v. Gulfstream Aerospace Corp.*, 995 F.2d 425, 429 (3d Cir.1993) (“The second [*Brunswick*] requirement is generally met if the plaintiff is a ‘competitor [ ] or a consumer in the relevant market.’ Alternatively, this requirement is fulfilled if there exists a ‘significant causal connection’ such that the harm to the plaintiff can be said to be ‘inextricably intertwined’ with the antitrust conspiracy.”) (quoting *McCready*, 457 U.S. at 484). Thus, neither the Supreme Court nor the Third Circuit has foreclosed a finding of antitrust injury simply because the plaintiff was not a

participant in the relevant market.<sup>25</sup> As a result, to the extent that Defendant moves to dismiss the Complaint on the basis that Plaintiffs cannot suffer antitrust injury in a relevant market in which it is not a participant, Defendant's motion is denied.<sup>26</sup>

### *Standing*

\*14 Defendant also makes the argument that Plaintiffs lack standing under Section 3 of the Clayton Act because “neither Drug Mart nor Jabo has alleged that they are parties to any contract with Becton, exclusionary or otherwise, prohibiting them from buying products from Becton's competitors.” (Def. Br. at 19).

Pursuant to this Court's March 23, 2007 Order, all parties were advised that the issue of Clayton Act standing would be addressed by way of separate motion. See CM/ECF Docket Entry Nos. 144, 146. As a result, the Court will not address the issues raised regarding same herein.<sup>27</sup>

### *Exclusive Dealing Allegations*

Defendant makes the global argument that the “heart of plaintiffs' monopolization, attempted monopolization and restraint of trade claims are the allegations of Becton's alleged ‘exclusionary’ contracts, ‘predatory sales tactics’ and ‘bundling’ practices. There are many paragraphs and pages making vague allegations about how Becton sought to ‘unfairly restrain and limit competition’ in the non-existent ‘Disposable Hypodermic Products’ market, but there are no specific allegations about what specific contracts, with what specific parties, affected competition in which specific market.” (Def Br. at 14). The crux of Defendant's argument is that, “plaintiffs allege no facts about which contracts are exclusive, which products they relate to, or who the parties are that are involved in those contracts.” (*Id.* at 15).

The Complaint alleges that “Becton used ‘commitment contracts’ ... [which] essentially required GPO members to deal exclusively with Becton for its Hypodermic Product needs.” (Compl., ¶ 59). The Complaint goes on to provide two examples of such “commitment contracts,” (1) “in or around 1998 Premier awarded Becton a 7.5 year sole-source contract,” and (2) “[i]n or around 1999, Becton provided another GPO, Novation, a \$1 million payment (in addition to the 3% administrative fees that it pays Novation) for a 4-year sole-source contract under which Becton would be the only vendor approved by Novation

to sell Disposable Hypodermic Products to Novation members.” (*Id.*). Moreover, the Complaint alleges that “[i]f a Class member desired to purchase Disposable Hypodermic Products from a manufacturer that was not the chosen sole-source contractor for the GPO, the Class member risked losing numerous financial incentives,” as a result, a “substantial portion of the markets for Disposable Hypodermic Products have been foreclosed.” (*Id.*, ¶¶ 60, 68).

In light of the foregoing allegations, the Court finds that Defendant’s argument that “there are no specific allegations about what specific contracts, with what specific parties, affected competition in which specific market” to be unpersuasive.<sup>28</sup> See, e.g., *Bell Atl. Corp.*, 127 S.Ct. at 1965 (“Asking for plausible grounds to infer an agreement does not impose a probability requirement at the pleading stage; it simply calls for enough fact to raise a reasonable expectation that discovery will reveal evidence of illegal agreement.”).

## II. Indirect Purchaser Claims

### A. Generally

\*15 In the alternative, Plaintiffs assert indirect purchaser claims under the laws of the District of Columbia and twenty-five other jurisdictions. Defendant moves to dismiss such “indirect” purchaser claims on the same basis on which it argues that Plaintiffs’ federal antitrust claims are deficient. (Def. Br. at 22). As discussed above, Plaintiffs’ claims will not be dismissed on these grounds.

Defendant also claims that “[t]here is an additional, and independent, reason for dismissing plaintiffs’ ‘indirect’ purchaser claims under state law: the Complaint fails to allege what portion, if any, of Becton’s alleged ‘overcharge’ was passed on to them.” (Def. Br. at 22). In particular, Defendant argues that, as indirect purchasers, Plaintiffs must prove that Becton charged monopoly prices and that Becton’s “overcharge” was passed on to Plaintiffs.

As a preliminary matter, the Court notes that Defendant cites to no legal authority indicating that Plaintiffs must plead the *amount* of “overcharge” which was passed on to them. Furthermore, although Defendant claims that “an indirect purchaser must allege and prove: (1) that a ‘direct’ purchaser (e.g., a wholesaler) was overcharged by Becton, (2) that the direct purchaser then passed on the overcharge, or some portion of it, to the ‘indirect’ purchaser, and (3) that the indirect purchaser did not turn around and pass on all of the overcharge to its customers,”<sup>29</sup> the cases relied upon

by Defendant in support of same—which are not binding on this Court, and none of which were decided at the motion to dismiss stage—do not dictate that the foregoing factors are a pleading requirement.<sup>30</sup> Therefore, the Court concludes that Defendant has not met its burden in demonstrating that Plaintiffs’ indirect purchaser claims should be dismissed on such a basis at this time.

### B. Standing<sup>31</sup>

Defendant makes the argument that Count IV of the Complaint (asserting various state antitrust law violations) should be dismissed because the named plaintiffs lack standing to bring claims in those states in which the named plaintiffs do not reside or engage in business. (Def. Br. at 24, 27). In particular, Defendant argues that Plaintiffs cannot acquire standing by asserting claims on behalf of “un-named, un-identified absent class members.”<sup>32</sup> (*Id.* at 25). The Court has considered Defendant’s argument in this regard, but, for the reasons that follow, declines to rule on the issue prior to addressing the issue of class certification.<sup>33</sup>

The Supreme Court has explained that “[w]hile an Article III court ordinarily must be sure of its own jurisdiction before getting to the merits, a Rule 23 question should be treated first because class certification issues are ‘logically antecedent’ to Article III concerns....” *Ortiz v. Fibreboard Corp.*, 527 U.S. 815, 816, 119 S.Ct. 2295, 144 L.Ed.2d 715 (1999). Here, Defendant’s argument that Plaintiffs do not enjoy standing to raise state antitrust claims in jurisdictions in which they do not reside or do business is an issue that would not arise unless class certification is granted. To be clear, the state antitrust claims alleged in Count IV of the Complaint are brought “*only* by the Indirect Class.” See Compl. at 24 (emphasis added). It follows that if the Court determines that Plaintiffs’ Indirect Class should not be certified, then Defendant’s concerns regarding the state antitrust claims—brought “*only* by the Indirect Class”—may prove to be moot. *Id.* Therefore, in accordance with *Ortiz*,<sup>34</sup> the Court will defer its consideration of this argument until after class certification issues have been resolved. See, e.g., *In re K-Dur Antitrust Litig.*, 338 F.Supp.2d at 544 (declining to address defendant’s argument that plaintiffs lack Article III standing to assert claims in jurisdictions in which plaintiffs do not allege to have been purchasers prior to determining class certification); *Clark v. McDonald’s Corp.*, 213 F.R.D. 198, 205 (2003) (declining to address defendant’s argument that plaintiff has no standing to assert claims on behalf of class members regarding restaurants in states that plaintiff,



himself, has not visited, and reasoning that such an issue “would not arise but for Clark’s capacity as a putative class representative.”); *In re Buspirone Patent Litig.*, 185 F.Supp.2d 363, 377 (S.D.N.Y.2002) (deferring on issue of Article III standing on a motion to dismiss, and explaining that “it is appropriate to decide class certification before resolving alleged Article III challenges of the present kind.”). As such, to the extent that Defendant moves to dismiss Plaintiffs’ state antitrust claims on such a basis, Defendant’s motion is denied, without prejudice.

### C. Unjust Enrichment Claims

\*16 Plaintiffs assert claims for unjust enrichment under the laws of the District of Columbia and twenty-five other jurisdictions. (Compl. at 27-28). Generally, “in order to state a claim for unjust enrichment, a plaintiff must allege (1) at plaintiff’s expense, (2) defendant received benefit, (3) under circumstances that would make it unjust for defendant to retain benefit without paying for it.” *In re K-Dur Antitrust Litig.*, 338 F.Supp.2d at 544 (citing *Restatement of Restitution* § 1 (1937)). Here, the Complaint alleges that “[a]s a result of Becton’s anticompetitive scheme alleged herein, Plaintiffs and the Class members paid too much for Becton Disposable Hypodermic Products. The payment of these ‘overcharges’ represents an unjust benefit Plaintiffs and Class members conferred upon Becton. Becton was unjustly enriched by these illegal overcharges and equity requires disgorgement to prevent Becton from benefitting from its illegal acts.” (Compl., ¶¶ 108, 112).

Defendant moves to dismiss Plaintiffs’ claims for unjust enrichment on the basis that such claims are redundant to the extent that they are “based on the same alleged facts and same alleged damages as their antitrust claims: that they ‘paid too much’ for Becton products and that the ‘overcharge’ was an ‘unjust benefit’ plaintiffs conferred on Becton.” (Def. Br. at 36). While Defendant may ultimately be correct, Plaintiffs are permitted to plead alternative theories of recovery. *See, e.g., In re K-Dur Antitrust Litig.*, 338 F.Supp.2d at 544 (denying motion to dismiss claims of unjust enrichment on the basis that equitable remedies such as unjust enrichment should not be granted where there exists an adequate remedy at law, and noting that plaintiffs “are clearly permitted to plead alternative theories of recovery.”); *United States v. Kensington Hosp.*, 760 F.Supp. 1120, 1135 (E.D.Pa.1991) (recognizing that under Pennsylvania law an underlying

contract precludes a claim of unjust enrichment, but allowing both claims to proceed, and explaining that the “Federal rules allow pleading in the alternative.”). Therefore, the Court finds that it would be premature to dismiss Plaintiffs’ unjust enrichment claims on such a basis at this stage of the litigation.

To the extent that Defendant moves to dismiss Plaintiffs’ claims of unjust enrichment on the basis that certain individual states impose additional requirements, such as privity and exhaustion of remedies, the Court likewise determines that it is premature to consider these requirements on a state by state basis, at this time. Because neither the “Indirect Class,” nor the “D.C. Indirect Class” has yet to be certified, the Court will not predict which state law(s) would be applicable in the event that said Classes are certified, “particularly given the fact that the anticipated complexity of a choice-of-law analysis may itself be a factor in determining the certifiability of the class.” *In re K-Dur Antitrust Litig.*, 338 F.Supp.2d at 541. Therefore, Defendant’s motion to dismiss Plaintiffs’ unjust enrichment claims is denied, without prejudice.

### D. State Antitrust Claims

\*17 Finally, Defendant argues that certain state antitrust claims asserted by Plaintiffs are deficient for various reasons, including, but not limited to (1) Plaintiffs’ inability to pursue claims under state antitrust laws which regulate only *intrastate* commerce, and (2) Plaintiffs’ inability to meet particular pleading and/or procedural requirements set forth by certain states. For the same reasons why the Court deems it inappropriate to determine under which state laws Plaintiffs have viable unjust enrichment claims, the Court likewise determines that it would be inefficient to assess (1) which state antitrust laws would be applicable, and (2) the viability of Plaintiffs’ state antitrust claims under such laws, *prior* to a determination on the issue of class certification.<sup>35</sup> Accordingly, to the extent that Defendant moves to dismiss Plaintiffs’ state antitrust claims on such a basis, Defendant’s motion is denied, without prejudice.

### CONCLUSION

For the reasons stated herein, the Court denies Defendant’s motion to dismiss the Consolidated Class Action Complaint. An appropriate Order accompanies this Opinion.

Footnotes



1 For purposes of the instant motion, Plaintiffs include Jabo's Pharmacy, Inc. and Drug Mart Tallman, Inc. (hereinafter collectively  
"Plaintiffs").

2 The operative complaint is the Consolidated Class Action Complaint, filed on May 10, 2006, hereinafter referred to as "Complaint."  
In the instant Opinion, the Court addresses *only* Defendant's motion to dismiss the Complaint filed by Jabo's Pharmacy, Inc. and  
Drug Mart Tallman, Inc. Defendant has filed separate motions to dismiss the complaints of other parties to this multidistrict litigation,  
which have been decided by the Court by way of separate opinions.

3 The Court decides this matter without oral argument. [Fed.R.Civ.P. 78](#). Jurisdiction is premised on [28 U.S.C. §§ 1331, 1337](#), and  
[15 U.S.C. § 15\(a\)](#).

4 For purposes of the instant motion to dismiss, the Court accepts Plaintiffs' factual allegations as true, and relies only on the Complaint.  
*See, e.g., Lum v. Bank of Am.*, 361 F.3d 217, 222 n. 3 (3d Cir.2004) ("In deciding motions to dismiss pursuant to [Rule 12\(b\)\(6\)](#), courts  
generally consider only the allegations in the complaint, exhibits attached to the complaint, matters of public record, and documents  
that form the basis of a claim.").

5 Defendant has also moved to dismiss (1) the Second Consolidated Amended Class Action Complaint filed by Louisiana Wholesale  
Drug Company, Inc., Rochester Drug Co-Operative, Inc., JM Smith d/b/a Smith Drug Company, Dik Drug Company, American Sales  
Company, Inc., Park Surgical Co. Inc. and SAJ Distributors, Inc., and (2) the Class Action Amended Complaint filed by Medstar  
Health, Inc., Medstar-Georgetown Medical Center, Inc., Washington Hospital Center Corporation and National Rehabilitation  
Hospital, Inc. As previously indicated, the foregoing motions will not be addressed herein.

6 In doing so, a court may look only to the facts alleged in the complaint and any accompanying attachments, and may not look at the  
record. *See Jordan v. Fox, Rothschild, O'Brien & Frankel*, 20 F.3d 1251, 1261 (3d Cir.1994).

7 In so holding, the United States Supreme Court rejected the language previously used by the Court in *Conley v. Gibson*, providing that  
"[i]n appraising the sufficiency of the complaint we follow, of course, the accepted rule that a complaint should not be dismissed for  
failure to state a claim unless it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would  
entitle him to relief." 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957). *See Bell Atl. Corp.*, 127 S.Ct. at 1964, 1974 (holding that  
the *Conley* "no set of facts" language "has earned its retirement" and "is best forgotten.").

8 *See, e.g., In re K-Dur Antitrust Litig.*, 338 F.Supp.2d 517 (D.N.J.2004); *In re Mercedes-Benz Anti-Trust Litig.*, 157 F.Supp.2d 355,  
359 (D.N.J.2001).

9 [Federal Rule of Civil Procedure 8\(a\)](#) provides that "[a] pleading which sets forth a claim for relief ... shall contain ... a short and plain  
statement of the claim showing that the pleader is entitled to relief."

10 *See also Associated Gen. Contractors of Cal., Inc. v. Carpenters*, 459 U.S. 519, 528 n. 17, 103 S.Ct. 897, 74 L.Ed.2d 723 (1983)  
(stating that "a district court must retain the power to insist upon some specificity in pleading before allowing a potentially massive  
factual controversy to proceed.").

11 In doing so, the Court is cognizant of the fact that "a formulaic recitation of a cause of action's elements" alone will not sustain  
Plaintiffs' obligation to provide the grounds of their entitlement to relief. *Bell Atl. Corp.*, 127 S.Ct. at 1959.

12 Given the foregoing allegations, the Court finds "plausible grounds to infer an agreement" between Defendant and certain GPOs and/  
or manufactures. *Bell Atl. Corp.*, 127 S.Ct. at 1965. *See generally Elder-Beerman Stores Corp. v. Federated Dept. Stores, Inc.*, 459  
F.2d 138, 146 (6th Cir.1972) ("The granting of exclusive selling rights or acceptance of such exclusive selling rights, acts which are  
not prohibited by law unless there is a resulting foreclosure of market alternatives cannot, without proof of such foreclosure, form  
the basis for a jury verdict that the defendants had entered into a conspiracy to restrain trade.").

13 *See, e.g., SmithKline Corp. v. Eli Lilly & Co.*, 575 F.2d 1056, 1065 (3d Cir.1978) (finding that "the act of willful acquisition and  
maintenance of monopoly power was brought about by linking products on which Lilly faced no competition Keflin and Keflex with  
a competitive product, Kefzol. The result was to sell all three products on a non-competitive basis in what would have otherwise been  
a competitive market for Ancef and Kefzol. The effect of the Revised CSP was to force SmithKline to pay rebates on one product,  
Ancef, equal to rebates paid by Lilly based on volume sales of three products.").

14 *See generally Schuykill Energy Res., Inc.*, 113 F.3d at 415 ("Thus, SER must allege that PP & L unlawfully acquired monopoly  
power or had a dangerous probability of unlawfully achieving monopoly power in its service area. To do this, SER must allege that  
PP & L in some way acted to exclude SER as a competitor in the delivery of electricity to customers in PP & L's service area .").

15 In particular, Defendant argues that "as a matter of federal law, safety and conventional devices are not interchangeable" and thus  
cannot be part of the same relevant market. (Def. Br. at 8). Even if Defendant is ultimately correct, the Court declines to engage in  
any such analysis at this time. *See, e.g., Ansell, Inc. v. Schmid Labs., Inc.*, 757 F.Supp. 467 (D.N.J.1991) (defining relevant product  
market after multi-day hearing, including expert testimony).

16 Moreover, Defendant's reliance on *E. & G. Gabriel v. Gabriel Bros., Inc.*, -a case which is not binding on this Court and distinguishable  
on a number of levels-is misplaced. No. 93-0894, 1994 WL 369147, at \*3 (S.D.N.Y. July 13, 1994) (finding plaintiff's proposed  
market, comprised of "products as varied as household hardwares and children's sleepwear," to be implausible, and reasoning that

“[h]ammers are obviously not reasonable substitutes for children's pajamas, they are not used for similar purposes, nor will the price of hammers affect the price of pajamas.”).

Throughout its papers, Defendant relies on a number of cases, which are not binding on this Court, for the proposition that Plaintiffs' have failed to plead with the requisite “particularity” or “specificity.” The Court has reviewed these decisions and finds that such cases do not warrant dismissal of Plaintiffs' claims on such a basis at this time. See, e.g., *JM Computer Servs., Inc. v. Schlumberger Techs., Inc.*, 1996 WL 241607, at \*4 (N.D.Cal. May 3, 1996) (granting defendant's motion to dismiss a § 2 claim where plaintiff (1) failed to “identify the specific products or services in product markets for which Plaintiff claims there is no price elasticity,” (2) failed to “identify an agreement with a specific person or entity,” and (3) “does not identify the parts, services, or contracts involved in the alleged exclusive dealing”).

Defendant also relies heavily on the Third Circuit's decision in *Garshman v. Universal Res. Holding Inc.*, 824 F.2d 223, 230-31 (3d Cir.1987). The Court has reviewed the *Garshman* decision and finds that the deficiencies alleged by Defendant in this case do not rise to the level of those contemplated by the Third Circuit in *Garshman*, where the complaint, itself, failed to allege *any* “adverse effect on competition in any relevant market.” *Id.* at 231 (stating that “[t]he allegation of unspecified contracts with unnamed other entities to achieve unidentified anticompetitive effects does not meet the minimum standards for pleading a conspiracy in violation of the Sherman Act.”).

While the Supreme Court indicated that “a plaintiff's obligation to provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and conclusions,” for the reasons stated herein, the Court finds that Plaintiffs have met this burden. *Bell Atl. Corp.*, 127 S.Ct. at 1959.

See also *In re Ins. Brokerage Antitrust Litig.*, No. 04-5184, 2007 WL 1100449, at \*8 (D.N.J. April 5, 2007) (utilizing heightened pleading standard of Federal Rule of Civil Procedure 9(b) where the plaintiffs' antitrust conspiracy claims were predicated on fraud).

Defendant reasserts this argument repeatedly throughout its papers. For purposes of efficiency, the Court will not revisit this issue herein.

In *Bell Atl. Corp.*, the plaintiffs alleged that the Incumbent Local Exchange Carriers “have entered into a contract, combination or conspiracy to prevent competitive entry in their respective local telephone and/or high speed internet services markets and have agreed not to compete with one another and otherwise allocated customers and markets to one another.” *Id.* at 1963.

The Court recognizes that “[t]he allegation of unspecified contracts with unnamed other entities to achieve unidentified anticompetitive effects does not meet the minimum standards for pleading a conspiracy in violation of the Sherman Act.” *Garshman v. Universal Res. Holding Inc.*, 824 F.2d 223, 230-31 (3d Cir.1987). Nevertheless, the Court does not find that the deficiencies alleged by Defendant in this case rise to the level of those contemplated by the Third Circuit in *Garshman*, where the complaint, itself, failed to allege *any* “adverse effect on competition in any relevant market.” *Id.* at 231.

See, e.g., *Bell Atl. Corp.*, 127 S.Ct. at 1960, 1964 (“A complaint attacked by a Rule 12(b)(6) motion to dismiss does not need detailed factual allegations,” only “enough facts to state a claim to relief that is plausible on its face.”).

See generally *Harrison Aire, Inc. v. Aerostar Intern., Inc.*, 423 F.3d 374, 385 (3d Cir.2005) (“Here, Harrison Aire is a consumer of balloon fabric, and it claims antitrust injury in the form of business losses caused by high fabric prices, which in turn allegedly were caused by Raven/Aerostar's exclusionary conduct in the relevant fabric market. This type of injury-prohibitively high consumer prices resulting from allegedly monopolistic behavior-is the type the antitrust laws are designed to redress.”).

Because Defendant does not argue that Plaintiffs' alleged injuries are not “inextricably intertwined” with Defendant's alleged actions in the relevant markets, the Court need not consider same.

Defendant also makes the related argument that Plaintiffs lack antitrust standing *generally* because they “have not alleged the facts that would give *them* standing to complain-e.g., that they actually buy conventional IV catheters, that the conduct alleged actually affected the price of conventional IV catheters, or that plaintiffs actually were injured by that conduct.” (Def. Br. at 17, 20) (emphasis in original). To the extent that the Court should construe such an argument as based on the theory that Plaintiffs cannot suffer antitrust injury in a relevant market in which it is not a participant, such an argument is, therefore, rejected.

To the extent that Defendant argues that Plaintiffs lack antitrust standing *generally* based on the theory that Plaintiffs have not alleged that they are direct purchasers of the Disposable Hypodermic Products at issue, the Court will, therefore, defer its consideration of this argument. See Def. Br. at 17, 20 (arguing that Plaintiffs lack standing because they “have not alleged the facts that would *them* standing to complain-e.g., that they actually buy conventional IV catheters, that the conduct alleged actually affected the price of conventional IV catheters, or that plaintiffs actually were injured by that conduct.”) (emphasis in original).

Furthermore, the Court has reviewed the unpublished decisions cited to by Defendant and finds that the types of deficiencies alleged by Defendant in this case do not rise to the level of the deficiencies found by the respective courts in those cases. See, e.g., *McPherson's, Ltd. v. Never Dull, Inc.*, 1990 WL 238812, \*4 (D.N.J.1990) (dismissing antitrust claims where the complaint contained merely a “boilerplate allegation of price discrimination without providing supporting facts.”); *JM Computer Servs., Inc. v. Schlumberger Techs., Inc.*, 1996 WL 241607, at \*4 (N.D.Cal. May 3, 1996) (granting defendant's motion to dismiss a § 2 claim where plaintiff

(1) failed to “identify the specific products or services in product markets for which Plaintiff claims there is no price elasticity,” (2) failed to “identify an agreement with a specific person or entity,” and (3) “does not identify the parts, services, or contracts involved in the alleged exclusive dealing”).

See *Silidor Decl.*, Ex. 4 at 23.

See *In re Methionine Antitrust Litig.*, 204 F.R.D. 161, 164 (N.D.Cal.2001); *A & M Supply Co. v. Microsoft Corp.*, 252 Mich.App. 580, 654 N.W.2d 572, 575 (Mich.Ct.App.2002); *Melnick v. Microsoft Corp.*, No. 99-709, 2001 WL 1012261, at \*6 (Me.Super.Ct. Aug. 24, 2001).

Moreover, to the extent that Defendant cites to *Illinois Brick Co. v. Illinois*, 431 U.S. 720, 97 S.Ct. 2061, 52 L.Ed.2d 707 (1977), for the proposition that “[a]n indirect purchaser plaintiff must prove that Becton charged monopoly prices and that all or some of Becton’s ‘overcharge’ was passed through the distribution chain from the first purchaser to the indirect purchaser plaintiff” (Def. Br. at 23), Defendant fails to indicate how Plaintiffs’ ultimate burden of proof is relevant at this stage of the litigation. See, e.g., *Scheuer*, 416 U.S. at 236 (explaining that, in conducting a 12(b)(6) analysis, the question is not whether plaintiffs will ultimately prevail in a trial on the merits, but whether they should be given an opportunity to offer evidence in support of their claims).

L. Civ. R. 7.2(b) imposes a 15 page limit for reply briefs when using a 14-point Times New Roman font, as was done in this case. Moreover, L. Civ. R. 7.2(b) specifically provides that “[b]riefs of greater length will only be accepted if special permission of the Judge or Magistrate Judge is obtained prior to submission of the brief.” Defendant’s reply brief totals 15 pages. However, Defendant’s reply brief also refers the Court to pages 8-14 of the reply brief it submitted in connection with its motion to dismiss the Second Consolidated Amended Class Action Complaint filed by Louisiana Wholesale Drug Company, Inc., Rochester Drug Co-Operative, Inc., JM Smith d/b/a Smith Drug Company, Dik Drug Company, American Sales Company, Inc., Park Surgical Co. Inc. and SAJ Distributors, Inc. See Def. Reply Br. at 2. Not only does this put Defendant well over the allotted 15 page limit, but such cross-referencing is both confusing and frustrating to the Court, and should therefore be avoided in all future filings. In any event, Defendant does not indicate that it sought, or was given, permission, to file an over-length reply brief in this instance. As a result, to the extent that pages 8-14 of the reply brief submitted in connection with Defendant’s motion to dismiss the Second Consolidated Amended Class Action Complaint filed by Louisiana Wholesale Drug Company, Inc., Rochester Drug Co-Operative, Inc., JM Smith d/b/a Smith Drug Company, Dik Drug Company, American Sales Company, Inc., Park Surgical Co. Inc. and SAJ Distributors, Inc. raise arguments not raised herein, the Court will not consider such arguments in connection with the instant motion to dismiss.

The Court notes that the cases cited to by Defendant in support of this argument are either not binding on this Court, or were decided before *Ortiz v. Fibreboard Corp.*, 527 U.S. 815, 119 S.Ct. 2295, 144 L.Ed.2d 715 (1999). See Def. Br. at 25.

Magistrate Judge Ronald J. Hedges’ March 28, 2007 Order indicates that motions for class certification will be forthcoming. See CM/ECF Docket Entry No. 146.

The Court is unpersuaded by Defendant’s contention that the *Ortiz* “logically antecedent” exception does not apply to the circumstances at hand. 527 U.S. 815, 119 S.Ct. 2295, 144 L.Ed.2d 715 (1999). (Def. Reply Br. at 3). As previously indicated, the state antitrust claims alleged in Count IV of the Complaint are brought “only by the Indirect Class.” See Compl. at 24 (emphasis added). Should the Court decide not to certify the Indirect Class, then Defendant’s concerns regarding claims “brought only by the Indirect Class” may be moot. *Id.*

See, e.g., *In re K-Dur Antitrust Litig.*, 338 F.Supp.2d at 542 (declining to address similar arguments regarding the deficiency of plaintiffs’ state antitrust claims, and explaining that it would be “inefficient to determine under which state laws the Indirect Purchasers have viable claims before first deciding the class certification and choice of law issues.”).